Plant Based Protein Expression Market Projected to Reach $5.81 Billion by 2035</h2>

The global plant-based protein expression market was valued at USD 2.42 billion in 2025 and is projected to reach USD 5.81 billion by 2035, with a compound annual growth rate (CAGR) of 7.68% during the forecast period of 2026 to 2035. This growth is driven by the increasing demand for biologics and the limitations of traditional production methods.

Biologics have seen a significant rise in popularity, a trend amplified post the COVID-19 pandemic. Currently, approximately 85% of drug candidates are produced using mammalian cell cultures. However, these systems face challenges including pathogen contamination risks, scale-up difficulties, decreased productivity, and byproduct formation. Furthermore, existing mammalian cell capacities are estimated to meet only 50% of the inflated demand for biologics.

Plant-based expression systems have emerged as a promising alternative due to advances in synthetic organic chemistry and molecular farming. These systems allow for the production of proteins with distinct and uniform post-translational modifications, leading to more effective biologics compared to those produced using mammalian or yeast-based cell cultures. Plant-based biologics are safer, posing a negligible risk of introducing human and animal pathogens. Additionally, they facilitate rapid (4-8 weeks) large-scale manufacturing with reportedly 25% lower operating costs than other systems.

Pharmaceutical companies are actively adopting plant-based expression systems for various recombinant proteins, including vaccine candidates, enzymes, therapeutic proteins, and monoclonal antibodies. Around 50 plant-based therapies are currently developed or under evaluation, with over 35 providers offering proprietary technologies. The market is expected to witness healthy growth due to increasing disease prevalence, rising demand for biologics, and ongoing efforts to optimize these technologies.